These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 2669140

  • 21. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
    Gladieff L, Chatelut E, Gaspard MH, Skaf R, de Forni M, Mihura J, Canal P, Bugat R.
    Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
    [Abstract] [Full Text] [Related]

  • 22. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 23. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.
    Gynecol Oncol; 1999 Apr 15; 73(1):96-101. PubMed ID: 10094887
    [Abstract] [Full Text] [Related]

  • 24. Gynecological malignancies.
    Schaebler DL, Schilder RJ, Young RC.
    Cancer Chemother Biol Response Modif; 1996 Apr 15; 16():564-91. PubMed ID: 8639401
    [Abstract] [Full Text] [Related]

  • 25. Irreversible renal failure after intraperitoneal cisplatin administration. A case report.
    Gouge SF, Tietjen DP, Moore J.
    J Reprod Med; 1989 Nov 15; 34(11):931-3. PubMed ID: 2585396
    [Abstract] [Full Text] [Related]

  • 26. Intraperitoneal chemotherapy in ovarian cancer.
    Hofstra LS, de Vries EG, Mulder NH, Willemse PH.
    Cancer Treat Rev; 2000 Apr 15; 26(2):133-43. PubMed ID: 10772970
    [Abstract] [Full Text] [Related]

  • 27. Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment.
    Markman M, Hakes T, Reichman B, Rubin S, Curtin J, Barakat R, Jones W, Lewis JL, Almadrones L, Hoskins W.
    Gynecol Oncol; 1993 May 15; 49(2):185-9. PubMed ID: 8504986
    [Abstract] [Full Text] [Related]

  • 28. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
    Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM.
    Crit Rev Oncol Hematol; 2007 May 15; 62(2):137-47. PubMed ID: 17188887
    [Abstract] [Full Text] [Related]

  • 29. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
    Han GR, Cai GF.
    Zhonghua Fu Chan Ke Za Zhi; 1993 Apr 15; 28(4):224-6, 254. PubMed ID: 8404307
    [Abstract] [Full Text] [Related]

  • 30. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.
    Forum (Genova); 2000 Apr 15; 10(4):323-32. PubMed ID: 11535983
    [Abstract] [Full Text] [Related]

  • 31. Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer.
    Hacker NF, Berek JS, Pretorius RG, Zuckerman J, Eisenkop S, Lagasse LD.
    Obstet Gynecol; 1987 Nov 15; 70(5):759-64. PubMed ID: 3658287
    [Abstract] [Full Text] [Related]

  • 32. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
    Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A, IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada.
    Gynecol Oncol; 2007 Jun 15; 105(3):747-56. PubMed ID: 17368522
    [Abstract] [Full Text] [Related]

  • 33. Chemotherapy in ovarian carcinoma: intravenous or intraperitoneal?
    Markman M.
    Hematol Oncol Clin North Am; 1988 Sep 15; 2(3):457-66. PubMed ID: 3053594
    [Abstract] [Full Text] [Related]

  • 34. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB, Marchetti DL, Baker TR, Blumenson LE.
    Gynecol Oncol; 1998 Sep 15; 70(3):392-7. PubMed ID: 9790793
    [Abstract] [Full Text] [Related]

  • 35. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G.
    Clin Cancer Res; 1998 Apr 15; 4(4):985-92. PubMed ID: 9563894
    [Abstract] [Full Text] [Related]

  • 36. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS.
    Semin Oncol; 1995 Oct 15; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [Abstract] [Full Text] [Related]

  • 37. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
    Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD.
    Gynecol Oncol; 1992 Apr 15; 45(1):3-8. PubMed ID: 1601332
    [Abstract] [Full Text] [Related]

  • 38. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
    Markman M, Reichman B, Hakes T, Jones W, Lewis JL, Rubin S, Almadrones L, Hoskins W.
    J Clin Oncol; 1991 Oct 15; 9(10):1801-5. PubMed ID: 1919630
    [Abstract] [Full Text] [Related]

  • 39. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.
    Markman M, George M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL.
    J Clin Oncol; 1990 Jan 15; 8(1):146-50. PubMed ID: 2295905
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.